SCHEMBL336273

SCHEMBL336273

COC(=O)c1ncc(-c2ccccc2)nc1NC(=O)C(F)(F)F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 1/20 0.46
IKBKB O14920 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.43
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 4/20 0.42
PRKDC P78527 3/20 0.41
ATR Q13535 3/20 0.41
HSD17B10 Q99714 3/20 0.40
HPGD P15428 2/20 0.40
IDO1 P14902 1/20 0.40
TDO2 P48775 1/20 0.40
LTB4R Q15722 1/20 0.40
MEN1 O00255 1/20 0.40
TP53 P04637 1/20 0.40
ADORA1 P30542 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL336700 0.83 SMN1; SMN2 (0.48) NPC1RAB9AMAPTIKBKBSMN1; SMN2
SCHEMBL336653 0.76 ATR (0.53) IKBKBSMN1; SMN2KDM4EALDH1A1PRKDC
SCHEMBL6057019 0.76 PDCD1 (0.48) NPC1RAB9AMAPTIKBKBSMN1; SMN2
SCHEMBL337769 0.76 ALDH1A1 (0.43) NPC1RAB9AIKBKBSMN1; SMN2KDM4E
SCHEMBL3460430 0.75 IKBKB (0.53) NPC1RAB9AMAPTIKBKBSMN1; SMN2
SCHEMBL3462566 0.74 ATR (0.66) PRKDCATR
SCHEMBL3461817 0.74 IKBKB (0.49) TRPM8NPC1RAB9AMAPTIKBKB
SCHEMBL3461782 0.73 IKBKB (0.48) NPC1RAB9AMAPTIKBKBSMN1; SMN2
SCHEMBL29907621 0.72 ALDH1A1 (0.48) IKBKBSMN1; SMN2KDM4EALDH1A1PRKDC
SCHEMBL13629341 0.71 IKBKB (0.46) NPC1RAB9AMAPTIKBKBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097620-B2 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2012-01-17 US disclosed
EP-2155746-A2 DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY Amgen, Inc (US) 2010-02-24 EP disclosed
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2009-04-16 US disclosed
WO-2008137084-A2 DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC. (US) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity EGLN3, EGLN2, HIF1AN TRPM8 4875/4885NPC1 2072/4885RAB9A 3899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.